Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical Inc. (LFCR) provides essential contract development and manufacturing services for sterile injectable pharmaceuticals and hyaluronic acid production. This news hub offers investors and industry professionals centralized access to official updates and analysis.
Track critical developments including regulatory milestones, manufacturing partnerships, and product innovation announcements. Our curated collection ensures timely access to earnings reports, facility expansions, and quality certifications that demonstrate LFCR's CDMO leadership.
All content undergoes rigorous verification to maintain accuracy and compliance with financial disclosure standards. Users benefit from organized updates on aseptic processing advancements, fermentation technology, and strategic collaborations within the biopharmaceutical sector.
Bookmark this page for streamlined monitoring of Lifecore Biomedical's operational progress and market positioning. Combine these verified updates with broader industry research to inform your analysis of this specialized pharmaceutical manufacturer.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the upcoming CDMO Live 2025 conference scheduled for May 7-8, 2025, in Rotterdam, Netherlands.
Jackie Klecker, Executive Vice President of Quality and Development Services at Lifecore, will chair a discussion titled 'Quality as a Catalyst: Accelerating CDMO Success Through Quality Management' on Wednesday, May 7, 2025, at noon local time. The session will feature external quality leaders from the CDMO industry exploring approaches to transform quality management into a strategic driver of CDMO partnerships.
Klecker brings over 30 years of industry experience in quality, manufacturing, and development, including more than a decade overseeing Lifecore's quality assurance.
Lifecore Biomedical (NASDAQ: LFCR) has announced the granting of equity inducement awards to Thomas D. Salus, their newly appointed chief legal and administration officer. The grants, approved on April 14, 2025, include:
- 45,000 restricted stock units (RSUs) vesting on the third anniversary
- 210,000 stock options vesting over three years
- 170,000 RSUs vesting in three annual installments
- Performance stock units (PSUs) of up to 370,000 shares based on stock price targets
The PSUs will vest based on achieving stock price targets ranging from $7.50 to $35.00 per share over a five-year performance period, with 50% of vested shares restricted from transfer for one year after vesting. These awards were granted under Lifecore's Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Lifecore Biomedical (NASDAQ: LFCR) has appointed Thomas (Tom) Salus as chief legal and administration officer and corporate secretary. Salus brings over 30 years of legal and management experience to the contract development and manufacturing organization (CDMO).
Salus joins from Viatris Inc., where he served as general counsel - corporate, securities & transactions and assistant secretary for 11 years. His experience includes roles at VWR International and PPL , along with positions at major law firms including Faegre Drinker Biddle & Reath LLP.
In his new role at Lifecore, Salus will oversee legal activities and human resources, while contributing to strategy development and corporate development activities focused on strategic alliances and partnerships. His expertise spans corporate governance, SEC reporting and compliance, complex business transactions, financings, and corporate compliance.
Lifecore Biomedical (NASDAQ: LFCR) reported Q3 fiscal 2025 financial results with revenues of $35.2 million, down 2% from $35.7 million in the prior year period. The company recorded a net loss of $14.8 million ($0.47 per share) compared to net income of $15.6 million in Q3 2024.
Key developments include:
- Multiple new development agreements signed with new and existing customers
- Sale of unused filler equipment for $17 million, strengthening balance sheet
- Adjusted EBITDA of $5.7 million, down from $6.4 million year-over-year
- Gross profit decreased to $9.8 million from $11.9 million
The company maintained its fiscal 2025 guidance, expecting revenue of $126.5-130 million and Adjusted EBITDA of $19-21 million.
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has scheduled its third quarter fiscal 2025 financial results announcement for Thursday, April 3, 2025, after market close.
The company's senior management team will host a webcast at 4:30 p.m. Eastern Time to discuss the quarterly results and recent corporate developments. The webcast will be accessible through Lifecore's Investor Events & Presentations webpage, with an archived version available for 30 days following the live presentation.
Lifecore Biomedical (NASDAQ: LFCR) has been selected by Humanetics to provide CDMO services for the development of BIO 300, a novel radioprotective agent. The collaboration focuses on preventing acute radiation syndrome, with development funded by the Department of Defense.
Under the agreement, Lifecore will handle technology transfer of the fill and finish process for BIO 300, including formulation development, gap assessment, and pilot batch filling. The company will also conduct analytical method work and feasibility assessments for future development.
BIO 300 is currently in late-stage clinical development for multiple applications, including:
- Mitigation of impaired pulmonary function in COVID-19 patients
- Protection of cancer patients from radiation therapy side effects
- Prevention of acute radiation syndrome for warfighters, First Responders, and civilians
The project is supported by a $5,132,520 award from the Department of Defense's Peer Reviewed Medical Research Program.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in three major upcoming conferences in March 2025.
The company will participate in the TD Cowen 45th Annual Health Care Conference in Boston (March 3-5), where CEO Paul Josephs will deliver a corporate presentation on March 4. Additionally, Lifecore will attend the KeyBanc Capital Markets Healthcare Forum (March 18-19) virtually, featuring a fireside chat with Mr. Josephs on March 19.
The company will also participate in DCAT Week 2025 in New York (March 17-20), engaging with current and prospective customers. A live webcast of the TD Cowen presentation will be available on Lifecore's investor website, with a replay accessible post-conference.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 2025 BIO CEO & Investor Conference. The event will be held on February 10-11, 2025, in New York, NY.
The company's management team, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will engage in one-on-one meetings during the conference. This participation demonstrates Lifecore's commitment to investor relations and market engagement.
Lifecore Biomedical (NASDAQ: LFCR) has announced a special stockholder meeting scheduled for April 10, 2025, to vote on removing the Convertible Preferred Stock Exchange Cap. This cap currently limits the conversion of Series A Preferred Stock to 19.99% of outstanding common stock prior to the issuance.
The proposal, if approved, would allow for potential conversion of Convertible Preferred Stock into a maximum of 6,056,284 shares of common stock based on the current conversion price. The meeting aligns with the terms of the January 9, 2023 Purchase Agreement. Stockholders of record as of February 18, 2025, will be eligible to vote.
The company emphasized that no holders have yet converted their preferred shares to common stock, and Lifecore currently has no plans to raise additional equity capital. A preliminary proxy statement will be filed with the SEC, followed by a definitive proxy statement with detailed meeting information.
Lifecore Biomedical (NASDAQ: LFCR) has announced the sale of its unused 10-head isolator filler for $17 million to a non-competitive buyer. The company received $7 million upfront, with the remaining amount to be paid in three installments over the next 18 months.
This strategic move follows the recent installation of a high-speed 5-head filler, which has doubled the company's available capacity. The new equipment supports up to $300 million in annual revenue, sufficient for Lifecore's mid-term and long-term growth objectives. The company is currently engaging with customers to utilize the new 5-head filler's speed and aseptic isolation capabilities.
